Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Blood

Volumn 123, Issue 19, 2014, Pages 2953-2959

  Kolstad, Arne ^a   Laurell, Anna ^b   Jerkeman, Mats ^c   Grønbæk, Kirsten ^d   Elonen, Erkki ^e   Räty, Riikka ^e   Pedersen, Lone Bredo ^d   Loft, Annika ^d   Bogsrud, Trond Velde ^f   Kimby, Eva ^g   Hansen, Per Boye ^h   Fagerli, Unn Merete ⁱ   Nilsson Ehle, Herman ^j   Lauritzsen, Grete Fossum ^a   Lehmann, Anne Kristine ^k   Sundstrom, Christer ^b   Karjalainen Lindsberg, Marja Liisa ^e   Ralfkiaer, Elisabeth ^d   Ehinger, Mats ^c   Delabie, Jan ^f   Bentzen, Hans ^l   Schildt, Jukka ^e   Kostova Aherdan, Kamelia ^b   Frederiksen, Henrik ^m   De Nully Brown, Peter ^d   Geisler, Christian H ^d   more..

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Mental Health Services CPH   (Denmark)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^j SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^k HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PROCEDURES; PROGNOSIS; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PROGNOSIS; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84900442345     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-541953     Document Type: Conference Paper

References (31)

1. Tiemann M, Schrader C, Klapper W, et al; European MCL Network. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131 (1):29-38. (Pubitemid 43899705)
2. Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer. 1998;34 (3):329-336. (Pubitemid 28183829)
3. Swerdlow SH, Berger F, Isaacson PI. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:168-170.
4. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23 (28):7013-7023.
5. Geisler CH, Kolstad A, Laurell A, et al; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112 (7):2687-2693.
6. Geisler CH, Kolstad A, Laurell A, et al; Nordic Lymphoma Group. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC1 autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158 (3):355-362.
7. van 't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol. 2009;144 (4):524-530.
8. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2008;26 (1):90-95.
9. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27 (31):5213-5218.
10. Smith MR, Li H, Gordon L, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30 (25):3119-3126.
11. Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118 (19):4706-4714.
12. Hoster E, Dreyling M, Klapper W, et al; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111 (2):558-565.
13. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50 (8):1257-1260.
14. Cheson BD, Horning SJ, Coiffier B, et al; NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17 (4):1244.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Geisler CH, Kolstad A, Laurell A, et al; Nordic Lymphoma Group. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115 (8): 1530-1533.
17. Zelenetz AD, Noy A, Pandit-Taskar N, et al. Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]. J Clin Oncol. 2006;24:436s. Abstract 7560.
18. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99 (9):3158-3162. (Pubitemid 34525293)
19. Morrison VA, Rai KR, Peterson BL, et al. Therapyrelated myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002; 20 (18):3878-3884.
20. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 2002;16 (12):2366-2378. (Pubitemid 36067289)
21. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non- Hodgkin's lymphoma patients. J Clin Oncol. 2003; 21 (5):897-906. (Pubitemid 46613489)
22. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25 (27): 4285-4292. (Pubitemid 47548569)
23. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25 (5):571-578. (Pubitemid 350002965)
24. Bodet-Milin C, Touzeau C, Leux C, et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging. 2010;37 (9):1633-1642.
25. Mato AR, Svoboda J, Feldman T, et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012;118 (14):3565-3570.
26. Cohen JB, Hall NC, Ruppert AS, et al. Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma. Bone Marrow Transplant. 2013;48 (9):1212-1217.
27. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25 (5): 579-586. (Pubitemid 350002966)
28. Andersen NS, Pedersen LB, Laurell A, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27 (26): 4365-4370.
29. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107 (6): 2271-2278. (Pubitemid 43345544)
30. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115 (16): 3215-3223.
31. Dreyling M, Kluin-Nelemans HC, Beà S, et al; European Mantle Cell Lymphoma Network. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2011; 52 (12):2226-2236.